Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Sponsor: Alliance Foundation Trials, LLC.
Listed as NCT05633654, this PHASE3 trial focuses on Triple Negative Breast Cancer and remains actively recruiting participants. Sponsored by Alliance Foundation Trials, LLC., it has been updated 28 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
28 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
▶ Show 23 earlier versions
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance Foundation Trials, LLC.
- GBG Forschungs GmbH
- Gilead Sciences
- NSABP Foundation Inc
For direct contact, visit the study record on ClinicalTrials.gov .